# Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

> **NCT01548144** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 178 (actual)

## Conditions studied

- Advanced Cancers

## Interventions

- **DRUG:** Crizotinib (Xalkori)
- **DRUG:** Pazopanib
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT01548144
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2021-08-26
- **Final completion:** 2021-08-26
- **Target enrollment:** 178 (ACTUAL)
- **Why stopped:** PI request
- **Last updated:** 2021-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01548144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01548144, "Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01548144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*